Fiduciary Alliance LLC Takes $247,000 Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Fiduciary Alliance LLC bought a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 3,960 shares of the company’s stock, valued at approximately $247,000.

Other hedge funds have also recently added to or reduced their stakes in the company. USA Financial Formulas acquired a new position in shares of TransMedics Group during the third quarter worth $55,000. Quarry LP increased its holdings in shares of TransMedics Group by 557.1% in the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after acquiring an additional 312 shares during the last quarter. National Bank of Canada FI raised its position in shares of TransMedics Group by 174.7% during the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company’s stock worth $65,000 after acquiring an additional 262 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in TransMedics Group by 187.0% during the third quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock worth $76,000 after purchasing an additional 316 shares during the last quarter. Finally, Rakuten Securities Inc. acquired a new position in TransMedics Group in the third quarter valued at approximately $126,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on TMDX shares. Canaccord Genuity Group lowered their target price on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a report on Wednesday, November 20th. Oppenheimer restated an “outperform” rating and issued a $125.00 price objective on shares of TransMedics Group in a research note on Tuesday, December 3rd. TD Cowen cut their target price on TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $75.00 target price (down from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Finally, Piper Sandler dropped their price target on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, TransMedics Group currently has an average rating of “Moderate Buy” and an average price target of $122.70.

TransMedics Group Price Performance

Shares of NASDAQ TMDX opened at $62.54 on Wednesday. The stock has a fifty day moving average price of $73.15 and a 200 day moving average price of $119.58. TransMedics Group, Inc. has a 1-year low of $58.27 and a 1-year high of $177.37. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The company has a market cap of $2.10 billion, a PE ratio of 66.53 and a beta of 2.12.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. During the same quarter last year, the business posted ($0.12) EPS. The firm’s revenue was up 63.7% on a year-over-year basis. Sell-side analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current year.

Insider Activity

In other news, Director Edward M. Basile sold 6,750 shares of the stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total value of $563,962.50. Following the completion of the transaction, the director now owns 732 shares in the company, valued at $61,158.60. This trade represents a 90.22 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Tamer I. Khayal sold 1,084 shares of the business’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $86.40, for a total transaction of $93,657.60. Following the sale, the insider now directly owns 20,843 shares in the company, valued at approximately $1,800,835.20. This represents a 4.94 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.00% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.